Charles Zhou
Stock Analyst at Guggenheim
(2.90)
# 1,508
Out of 5,140 analysts
9
Total ratings
71.43%
Success rate
39.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $39.90 | -49.87% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $165.96 | -18.05% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $23.93 | -33.14% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.75 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.06 | +5,183.02% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $2.59 | +1,676.06% | 1 | Jun 28, 2021 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $39.90
Upside: -49.87%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $165.96
Upside: -18.05%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $23.93
Upside: -33.14%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.06
Upside: +5,183.02%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $2.59
Upside: +1,676.06%